Cargando…

Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia

Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhatabi, Heba, Bin Saddeq, Haneen Abdulfattah, Alyamani, Luay, Shinawi, Thoraia, Yasin, Elrashed B., Alserihi, Raed, Felimban, Raed, Tayeb, Hossam H., Mimani, Rawan, Alalla, Zainab, Abu-Elmagd, Muhammad, Abuzenadah, Adel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701864/
https://www.ncbi.nlm.nih.gov/pubmed/34946913
http://dx.doi.org/10.3390/genes12121963
_version_ 1784621106107252736
author Alkhatabi, Heba
Bin Saddeq, Haneen Abdulfattah
Alyamani, Luay
Shinawi, Thoraia
Yasin, Elrashed B.
Alserihi, Raed
Felimban, Raed
Tayeb, Hossam H.
Mimani, Rawan
Alalla, Zainab
Abu-Elmagd, Muhammad
Abuzenadah, Adel
author_facet Alkhatabi, Heba
Bin Saddeq, Haneen Abdulfattah
Alyamani, Luay
Shinawi, Thoraia
Yasin, Elrashed B.
Alserihi, Raed
Felimban, Raed
Tayeb, Hossam H.
Mimani, Rawan
Alalla, Zainab
Abu-Elmagd, Muhammad
Abuzenadah, Adel
author_sort Alkhatabi, Heba
collection PubMed
description Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators.
format Online
Article
Text
id pubmed-8701864
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87018642021-12-24 Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia Alkhatabi, Heba Bin Saddeq, Haneen Abdulfattah Alyamani, Luay Shinawi, Thoraia Yasin, Elrashed B. Alserihi, Raed Felimban, Raed Tayeb, Hossam H. Mimani, Rawan Alalla, Zainab Abu-Elmagd, Muhammad Abuzenadah, Adel Genes (Basel) Article Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators. MDPI 2021-12-09 /pmc/articles/PMC8701864/ /pubmed/34946913 http://dx.doi.org/10.3390/genes12121963 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alkhatabi, Heba
Bin Saddeq, Haneen Abdulfattah
Alyamani, Luay
Shinawi, Thoraia
Yasin, Elrashed B.
Alserihi, Raed
Felimban, Raed
Tayeb, Hossam H.
Mimani, Rawan
Alalla, Zainab
Abu-Elmagd, Muhammad
Abuzenadah, Adel
Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
title Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
title_full Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
title_fullStr Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
title_full_unstemmed Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
title_short Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
title_sort investigation of isocitrate dehydrogenase 1 and 2 mutations in acute leukemia patients in saudi arabia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701864/
https://www.ncbi.nlm.nih.gov/pubmed/34946913
http://dx.doi.org/10.3390/genes12121963
work_keys_str_mv AT alkhatabiheba investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT binsaddeqhaneenabdulfattah investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT alyamaniluay investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT shinawithoraia investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT yasinelrashedb investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT alserihiraed investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT felimbanraed investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT tayebhossamh investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT mimanirawan investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT alallazainab investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT abuelmagdmuhammad investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia
AT abuzenadahadel investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia